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We are pleased to learn that another group also involved for
several years in the study of neoadjuvant treatment of colorec-
tal liver metastases share many of our views on the develop-
ment of hepatic vascular lesions induced by oxaliplatin-based
chemotherapy. The letter of Sebagh et al. raises several inter-
esting questions about the histological interpretation of the
hepatic lesions. In the planning phases of the study, the parti-
cipating pathologists reviewed together more than half of the
slides and reached a consensus on the definition and coding of
the lesions. Although this joint session may not have elimi-
nated all interobserver variation, they are likely to have
reduced it considerably. Our goal was to describe the lesions
most likely to be related to the use and the type of neoadju-
vant chemotherapy, rather than providing an exhaustive
assessment of the histopathological changes in the livers
examined. Since neither prevalence nor severity of portal
fibrosis and steatosis were significantly different between
patients receiving chemotherapy or not, we opted not to report
these data. The discrepancy between Sebagh’s and our group
concerning the type of vascular lesions may be more related
to the definition of the term than to actual differences.
Traditionally, the term ‘hepatic veno-occlusive disease’
refers to a form of toxic liver injury characterised clinically
by the development of hepatomegaly, ascites and jaundice,
and histologically by diffuse damage in the centrilobular zone
of the liver. Recent studies suggest that the primary site of the
toxic injury is initially the sinusoidal endothelial cells, fol-
lowed by a series of biological processes that lead to circula-
tory compromise of centrilobular hepatocytes, fibrosis,
obstruction of liver blood flow and eventually to alterations of
the centrilobular vein. The cardinal histological features of
this injury are marked sinusoidal dilatation and congestion,
necrosis of pericentral hepatocytes, narrowing and, only even-
tually, fibrosis of centrilobular veins. Based on these data,
DeLeve et al. [1] recently proposed a more appropriate name
for veno-occlusive disease, namely ‘sinusoidal obstruction
syndrome’ (SOS).
At the present time, making the diagnosis of vascular toxic
injury based exclusively on the presence of fibrotic veno-
occlusive lesion would appear too restrictive. The discrepancy
in frequency of the lesions detected by our two groups is prob-
ably less pronounced than suggested by Sebagh et al. In fact,
if four out of five of our patients receiving oxaliplatin-based
chemotherapy developed sinusoidal lesions, these were, as
specified in our paper, of variable degree and semi-quantitat-
ively evaluated. We observed 28% of severe vascular lesions
and 36% of moderate or mild lesions, but no mild lesions
were seen in patients who did not receive chemotherapy. In
Sebagh’s unpublished series, 38% of the 52 oxaliplatin-treated
patients developed severe vascular lesions. The frequency of
severe lesion is thus at least equivalent, if not greater, than the
frequency we detected. Their data appear to confirm that vas-
cular lesions are common in post-chemotherapy liver speci-
mens. This is interesting also because it suggests that the
chromomodulated infusion of chemotherapy in their patients
does not seem to reduce liver toxicity. As we stated in the
article, our ability to evaluate the clinical relevance of our
findings was limited by the retrospective nature of this study.
While we agree that the key end point is the clinical impact of
SOS lesions, an increase in operative mortality appears to be
Figure 1. (A) Macroscopically normal liver. (B) Post neoadjuvant oxaliplatin-based chemotherapy. The surface of the liver shows extensive areas of
congestion.
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too restrictive a parameter. Indeed, severe SOS can be ident-
ified macroscopically (Figure 1) or histologically in preopera-
tive frozen sections. By making the surgeon aware of this
lesion, a large resection can be avoided or more extensive por-
tal embolisation can be used before surgery to reduce the risk
of post-operative liver failure.
Since the recent publication of our paper we have become
aware of several cases of patients developing complications
(with long hospitalisations in intensive care unit) because of
the delay in liver regeneration and liver insufficiency after
limited hepatectomy (unpublished data). A patient has devel-
oped acute fatal portal hypertension after oxaliplatin-based
adjuvant chemotherapy for colorectal carcinoma [2]. The pub-
lication of such observations in the near future will support
the concept that SOS is a real and relevant clinical entity in
oxaliplatin-based chemotherapy.
In our experience, oxaliplatin is a very useful drug that
yields excellent responses in hepatic colorectal metastases,
and we believe that its use will continue to increase. There-
fore, far from intending to question the efficacy of oxaliplatin
in the treatment of colorectal metastasis, we suggest that the
occurrence of clinically significant secondary effects on the
liver need to be recognised to increase the safety of liver sur-
gery. The scope of these observations may further expand as
oxaliplatin is becoming used as adjuvant therapy in the treat-
ment of several other malignancies.
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We read with great interest the article by Berclaz et al. [1],
which stated that body mass index (BMI) is an independent
prognostic factor for overall survival in patients with breast
cancer, especially among pre-/perimenopausal patients treated
with chemotherapy without endocrine therapy. These authors
proposed different explanations for this association. We would
like to mention another explanation.
Amenorrhea is also an important prognostic factor for pre-
dicting the efficacy of chemotherapy in premenopausal
patients [2]. It is known that obese women have a longer
reproductive life and that longer exposure to estrogen
increases breast cancer risk. Although there were insufficient
data to demonstrate that chemotherapy is associated with a
decreased incidence of amenorrhea in obese patients compared
with lean counterparts, Mehta et al. [3] showed that 71% of
obese patients develop amenorrhea after receiving chemother-
apy, compared with 80% of non-obese breast cancer patients.
In light of the above information, we propose that obesity
itself, by suppressing the amenorrhea associated with che-
motherapy, may result in poorer prognosis in premenopausal
breast cancer patients with a high BMI.
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Reply to the Letter to the Editor
on “Obesity may decrease the
amenorrhea associated with
chemotherapy in premenopausal
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Altundag and colleagues suggest that obese women have an
increased breast cancer risk due to a longer reproductive life.
A meta-analysis of 23 studies providing information on
body mass index incidence in premenopausal breast cancer
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